Genetic Testing: ​A Cornerstone in Cardiomyopathy Management

Why Genetic⁤ Testing Is Key

Genetic testing is emerging as a critical tool in the management of cardiomyopathies,⁢ offering profound insights for risk stratification and patient care. Sharlene M. Day, MD,‍ a leading cardiomyopathy specialist and presidential professor at the Perelman School of ‍Medicine at the University of​ Pennsylvania, ⁤emphasizes ‌its importance. In an editorial accompanying a recent journal article, Dr. Day highlighted that the study’s data can ⁤inform risk stratification even in healthy individuals with incidental or secondary findings. ⁣She advocates for‍ the integration of genetic findings into cardiomyopathy‌ management as a “priority for all practicing cardiologists.”

Dr. ‍Day noted a narrowing knowledge gap regarding the significance of genetic testing in cardiomyopathy‌ patients. however, she also ⁣pointed out that⁣ “there’s still opportunity to improve recommendations and‍ referrals by cardiologists for genetic counseling and⁣ testing.”

Typically, genetic testing involves a comprehensive ‌panel that identifies multiple‍ gene variants, including‌ those in the Lmnana gene.if a specific gene variant ‌is identified in a patient, cascade testing of family members for that same variant is often recommended.

“The current research⁣ study ​nicely highlights the impact of⁣ identifying not only ⁣the specific⁣ gene involved⁤ but the​ type of ⁣variation within that gene in terms of ⁤risk stratifying patients for adverse​ outcomes,” Dr. day stated.

Impact on Future Cardiology Guidelines

The findings from this research are poised to influence future clinical practice guidelines, ‍notably in refining risk stratification⁢ for patients with dilated cardiomyopathy. Experts like Dr. Lakdawala suggest that future guidelines should underscore ⁣the value of a genetic diagnosis for ‍predicting adverse outcomes​ such as sudden ‍death ‌and heart failure.

Current guidelines already ⁤reflect the growing understanding of genetic influences. The ⁢most recent⁢ heart failure guidelines from the American College of Cardiology and the American​ Heart Association ⁢(ACC/AHA) provide a ‍Class 2A recommendation for implantable cardioverter-defibrillator (ICD)⁣ placement in patients with high-risk genes for dilated cardiomyopathy and an ⁣ejection fraction (EF) of 45% or lower. The guidelines ‍also suggest that primary preventive ICDs may be considered for individuals with a⁢ higher EF.

The 2023 European Cardiomyopathy Guideline ⁣further supports the role⁤ of genetic testing, recommending ICD placement in ⁣patients with Lmnana variants and an EF above 35%. This recommendation is classified ​as Class ⁢2A if risk factors are present and Class ​2B if no risk factors are identified.

Dr. Day suggests that for updated guidelines, a key ⁣refinement would ⁢be to​ enhance the Lmnana risk score for ventricular arrhythmias by incorporating the specific type‌ and location of the Lmnana variant.

“Genetic testing has clinical ramifications ⁣that will help cardiologists take better care of ‌their patients,” Dr. Lakdawala ‌concluded. “The take-home message is that they should order these tests!”

**

lakdawala reported ‍receiving personal fees from⁣ Alexion, Bayer, Bristol Myers Squibb, Cytokinetics, Lexeo⁢ Therapeutics, Nuevocor, Pfizer, and Tenaya Therapeutics‍ and grants from Bristol⁢ Myers Squibb and Pfizer. Day reported serving as chair of the steering ⁣committee for‍ Lexicon Pharmaceuticals, on⁢ the data monitoring‍ committee for Cytokinetics, and‍ receiving grants from Bristol Myers⁣ Squibb. Katherine Wandersee has more than 30⁣ years’ experience as a medical writer for​ professional medical audiences.*